Examples of in vivo uses include therapy with 177Lu-labeled PSMA (Prostate-specific membrane antigen) for the treatment of metastatic castration-resistant prostate cancer (12) as well as labeling of somatostatin analogs for the treatment of neuroendocrine tumors (13). This evidence concerns the gene FOLH1 and neuroendocrine neoplasm.